Core Insights - The U.S. liver cirrhosis treatment market is projected to reach approximately $15 billion by 2030, highlighting significant growth potential in this sector [3]. Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases, with its lead drug candidate Namodenoson showing promise in treating decompensated liver cirrhosis [1][5]. - Namodenoson is currently undergoing multiple clinical trials, including a pivotal Phase III trial for advanced liver cancer and a Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis (MASH) [4][5]. Clinical Development - A patient treated with Namodenoson under a compassionate use program has shown significant improvements, including the resolution of moderate ascites and a decrease in liver stiffness, indicating the drug's potential effectiveness [2][3]. - The positive response to Namodenoson is particularly noteworthy given the limited treatment options for decompensated liver disease, which often leads to liver transplantation [3]. Market Need - In 2017, approximately 10.6 million people globally were affected by decompensated cirrhosis, underscoring the urgent need for new therapeutic options as many patients face long wait times for liver transplants [3]. - The American Liver Foundation has indicated a critical shortage of donor organs, with some patients waiting over five years for a transplant, further emphasizing the market opportunity for effective treatments like Namodenoson [3].

Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [5] - The company is currently advancing its lead drug candidate, Namodenoson, which is being evaluated in multiple clinical trials for liver and other cancers [5] Clinical Development - Namodenoson has shown promising results in treating decompensated liver cirrhosis, with a patient experiencing significant symptom improvement after 20 months of treatment [2][3] - The treatment led to the disappearance of episodes of decompensated liver cirrhosis and improvements in liver stiffness and elevated globulin levels, markers of advanced liver disease [2][3] Market Potential - The U.S. market for liver cirrhosis treatment is projected to grow to approximately $15 billion by 2030, highlighting the urgent need for effective therapies [3] - In 2017, an estimated 10.6 million people globally were affected by decompensated cirrhosis, indicating a significant patient population in need of treatment options [3] Drug Profile - Namodenoson is an orally bioavailable drug that selectively binds to the A3 adenosine receptor, which is highly expressed in diseased cells, contributing to its favorable safety profile [4] - The drug has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for hepatocellular carcinoma by the FDA [5]

Core Insights - Can-Fite BioPharma Ltd. is hosting a webinar on February 25, 2025, to discuss its development pipeline and milestones [1][2] - The company has multiple out-licensing deals and potential regulatory and sales milestone payments exceeding $130 million, with $20 million already received [2] - Can-Fite's advanced-stage assets target unmet medical needs in markets valued over $70 billion, positioning the company for potential commercialization [2] Company Overview - Can-Fite BioPharma Ltd. is focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [1][4] - The lead drug candidate, Piclidenoson, has reported positive Phase III trial results for psoriasis and is set to begin a pivotal Phase III trial [4] - Namodenoson, another key drug, is in various stages of clinical trials for conditions such as Metabolic Dysfunction-associated Steatohepatitis (MASH) and hepatocellular carcinoma (HCC) [4] - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC treatment [4] - CF602, a third drug candidate, has shown efficacy in treating erectile dysfunction [4] Financial Highlights - Can-Fite has secured $20 million in upfront and milestone payments, indicating strong potential for its therapies [2] - The company is strategically positioned to capitalize on a market with a combined value exceeding $70 billion [2]

Core Insights - Can-Fite BioPharma Ltd. is hosting a webinar on February 25, 2025, to discuss its development pipeline and milestones [1][2] - The company has multiple out-licensing deals and potential regulatory and sales milestone payments exceeding $130 million, with $20 million already received [2] - Can-Fite's advanced-stage assets target unmet medical needs in markets valued over $70 billion, positioning the company for potential commercialization [2] Company Overview - Can-Fite BioPharma Ltd. is focused on developing small molecule drugs for oncological and inflammatory diseases, with a lead drug candidate, Piclidenoson, recently reporting Phase III trial results for psoriasis [4] - The company is also evaluating Namodenoson in various trials, including a Phase IIb for Metabolic Dysfunction-associated Steatohepatitis (MASH) and a Phase III for hepatocellular carcinoma (HCC) [4] - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC treatment [4] - CF602, another drug candidate, has shown efficacy in treating erectile dysfunction, with all drugs demonstrating a strong safety profile in over 1,600 patients [4]

Core Insights - Can-Fite BioPharma Ltd. is set to present at the BIO CEO & Investor Conference on February 10-11, 2025, in New York City, focusing on its business strategy and clinical milestones [1][2]. Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company specializing in small molecule drugs for oncological and inflammatory diseases, targeting multi-billion-dollar markets [4]. - The company’s lead drug candidate, Namodenoson, is currently in a pivotal Phase III trial for advanced liver cancer and a Phase IIb study for Metabolic Dysfunction-associated Steatohepatitis (MASH) [3][4]. - Another key drug candidate, Piclidenoson, is preparing to enter a pivotal Phase III trial for psoriasis [3][4]. - Can-Fite's third drug candidate, CF602, has shown efficacy in treating erectile dysfunction [4]. Clinical Development - Namodenoson has received Orphan Drug Designation in the U.S. and Europe and Fast Track Designation for HCC treatment by the U.S. FDA [4]. - The company has reported positive topline results for Piclidenoson in a Phase III trial for psoriasis and is expected to advance further [4]. - Can-Fite has conducted clinical studies involving over 1,600 patients, demonstrating an excellent safety profile for its drug candidates [4]. Presentation Details - The presentation at the BIO CEO & Investor Conference will be led by Motti Farbstein, the Chief Executive & Chief Financial Officer, on February 10, 2025, at 3:45 pm EST [6]. - The management team will hold one-on-one meetings with investors and potential partners to discuss the company's future development plans [2].

Namodenoson Drug Development - Namodenoson, a small orally bioavailable drug, has been granted a US patent for its use as an anti-obesity drug, valid until 2042 [1][2] - The drug is currently being developed for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH), advanced liver cancer, and pancreatic cancer [1][6] - In clinical studies, Namodenoson demonstrated a favorable safety profile and a 2.3% weight loss in patients after 3 months, with increased serum adiponectin levels [1][3] Anti-Obesity Mechanism and Market Potential - Namodenoson reduces fat levels by increasing adiponectin, a hormone that regulates fat production, and has shown weight loss in animal models of obesity [3] - The global obesity treatment industry is projected to reach $60.5 billion by 2030, with a compound annual growth rate of 22.3% from 2025 to 2030 [5] Can-Fite BioPharma Overview - Can-Fite BioPharma is an advanced clinical-stage drug development company focusing on cancer, liver, and inflammatory diseases [8] - The company's platform technology targets multi-billion dollar markets, with Namodenoson being a key drug candidate in Phase III trials for liver cancer and Phase IIb trials for MASH [6][8] - Namodenoson has received Orphan Drug Designation in the US and Europe and Fast Track Designation for hepatocellular carcinoma (HCC) treatment [8]

Core Viewpoint - Can-Fite Biopharma Ltd (CANF) has received a Zacks Rank 1 (Strong Buy) upgrade due to a positive trend in earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Can-Fite Biopharma indicates an expected earnings per share (EPS) of -$1.25 for the fiscal year ending December 2024, reflecting a 30.2% change from the previous year's reported number [9]. - Over the past three months, the Zacks Consensus Estimate for Can-Fite Biopharma has increased by 95.5%, indicating a strong upward revision trend [9]. Zacks Rating System - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for predicting near-term stock price movements [2][3]. - The system classifies stocks into five groups, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [8]. - Can-Fite Biopharma's upgrade to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [11].

Can-Fite’s data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases, today announced that its work titled “The Liver Protective Effect of the anti-Cancer Drug Candidate N ...

Can-Fite's data will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium Can-Fite enrolls patients for its pivotal Phase III advanced liver cancer study Ramat Gan, Israel, Dec. 30, 2024 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address Oncology and Inflammatory diseases, today announced that its work titled "The Liver Protective Effect of the anti-Cancer Drug Candidate Namodenoson ...

Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces the dosing of the first patient in the Phase IIa  clinical trial in patients with advanced pancreatic adenocarcinoma (NCT06387342).  “We are excited to have the first patient enrolled and hope ...